Role of glutathione in cancer progression and chemoresistance

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Traverso, Nicola ^a   Ricciarelli, Roberta ^a   Nitti, Mariapaola ^a   Marengo, Barbara ^a   Furfaro, Anna Lisa ^a   Pronzato, Maria Adelaide ^a   Marinari, Umberto Maria ^a   Domenicotti, Cinzia ^a  

^a Section of General Pathology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER AGENTS; ANTIOXIDANT CAPACITY; CANCER PROGRESSION; CELL DIFFERENTIATION; CELLULAR PROCESS; CHEMORESISTANCE; CYTOPROTECTIVE EFFECTS; CYTOTOXIC EFFECTS;

CELL DEATH; CHEMICAL COMPOUNDS; CYTOTOXICITY; PEPTIDES;

DISEASES;

ARSENIC TRIOXIDE; CYCLOPHOSPHAMIDE; DISULFIRAM; GLUTATHIONE;

BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL PROTECTION; COLON CANCER; CYTOTOXICITY; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; NONHUMAN; OVARY CANCER; REVIEW; SYNTHESIS; ANIMAL; BIOSYNTHESIS; DISEASE COURSE; DRUG RESISTANCE; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; NEOPLASMS;

EID: 84878711134     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/972913     Document Type: Review

References (123)

1. Dröge W., Free radicals in the physiological control of cell function. Physiological Reviews 2002 82 1 47 95 2-s2.0-0036086130 (Pubitemid 34654215)
2. Valko M., Leibfritz D., Moncol J., Cronin M. T. D., Mazur M., Telser J., Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry and Cell Biology 2007 39 1 44 84 2-s2.0-33749986298 10.1016/j.biocel.2006.07.001 (Pubitemid 44566469)
3. Landriscina M., Maddalena F., Laudiero G., Esposito F., Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxidants and Redox Signaling 2009 11 11 2701 2716 2-s2.0-73449095488 10.1089/ars.2009.2692
4. Hussain S. P., Hofseth L. J., Harris C. C., Radical causes of cancer. Nature Reviews Cancer 2003 3 4 276 285 2-s2.0-0038352053 (Pubitemid 37328863)
5. Cabello C. M., Bair W. B. III, Wondrak G. T., Experimental therapeutics: targeting the redox Achilles heel of cancer. Current Opinion in Investigational Drugs 2007 8 12 1022 1037 2-s2.0-36849034493 (Pubitemid 350224328)
6. Lecane P. S., Karaman M. W., Sirisawad M., Naumovski L., Miller R. A., Hacia J. G., Magda D., Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Research 2005 65 24 11676 11688 2-s2.0-29244453628 10.1158/0008-5472.CAN-05-2754 (Pubitemid 41821728)
7. Wang J., Yi J., Cancer cell killing via ROS: to increase or decrease, that is a question. Cancer Biology and Therapy 2008 7 12 1875 1884 2-s2.0-58149105356
8. Meister A., Glutathione metabolism. Methods in Enzymology 1995 251 3 7 2-s2.0-0029007943 10.1016/0076-6879(95)51106-7
9. Sies H., Glutathione and its role in cellular functions. Free Radical Biology and Medicine 1999 27 9-10 916 921 2-s2.0-0033230043 10.1016/S0891- 5849(99)00177-X (Pubitemid 29507465)
10. Calvert P., Yao K. S., Hamilton T. C., O'Dwyer P. J., Clinical studies of reversal of drug resistance based on glutathione. Chemico-Biological Interactions 1998 111-112 213 224 2-s2.0-18544399201 10.1016/S0009-2797(98) 00008-8 (Pubitemid 28271946)
11. Estrela J. M., Ortega A., Obrador E., Glutathione in cancer biology and therapy. Critical Reviews in Clinical Laboratory Sciences 2006 43 2 143 181 2-s2.0-33744994567 10.1080/10408360500523878 (Pubitemid 43860449)
12. O'Brien M. L., Tew K. D., Glutathione and related enzymes in multidrug resistance. European Journal of Cancer A 1996 32 6 967 978 2-s2.0-0029954846 10.1016/0959-8049(96)00051-2
13. Griffith O. W., Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. The Journal of Biological Chemistry 1982 257 22 13704 13712 2-s2.0-0020444895 (Pubitemid 13187133)
14. O'Dwyer P. J., Hamilton T. C., LaCreta F. P., Gallo J. M., Kilpatrick D., Halbherr T., Brennan J., Bookman M. A., Hoffman J., Young R. C., Comis R. L., Ozols R. F., Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Journal of Clinical Oncology 1996 14 1 249 256 2-s2.0-9044254931 (Pubitemid 26020021)
15. Wu J. H., Batist G., Glutathione and glutathione analogues, therapeutic potentials. Biochimica et Biophysica Acta 2012 1830 5 3350 3353
16. Nguyen T., Nioi P., Pickett C. B., The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. The Journal of Biological Chemistry 2009 284 20 13291 13295 2-s2.0-67649402187 10.1074/jbc.R900010200
17. Lu S. C., Regulation of glutathione synthesis. Molecular Aspects of Medicine 2009 30 1-2 42 59 2-s2.0-65049089113 10.1016/j.mam.2008.05.005
18. Meister A., Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacology and Therapeutics 1991 51 2 155 194 2-s2.0-0026343403
19. Oppenheimer L., Wellner V. P., Griffith O. W., Meister A., Glutathione synthetase. Purification from rat kidney and mapping of the substrate binding sites. The Journal of Biological Chemistry 1979 254 12 5184 5190 2-s2.0-0018801016
20. Luo J. L., Hammarqvist F., Andersson K., Wernerman J., Surgical trauma decreases glutathione synthetic capacity in human skeletal muscle tissue. American Journal of Physiology 1998 275 2, part 1 E359 E365 2-s2.0-0031846919 (Pubitemid 28391817)
21. Lu S. C., Regulation of hepatic glutathione synthesis: current concepts and controversies. The FASEB Journal 1999 13 10 1169 1183 2-s2.0-0033067354 (Pubitemid 29300363)
22. Meister A., On the discovery of glutathione. Trends in Biochemical Sciences 1988 13 5 185 188 2-s2.0-0024002527
23. Townsend D. M., Tew K. D., Tapiero H., The importance of glutathione in human disease. Biomedicine and Pharmacotherapy 2003 57 3 145 155 2-s2.0-0037733975 10.1016/S0753-3322(03)00043-X (Pubitemid 36740460)
24. Morel Y., Barouki R., Repression of gene expression by oxidative stress. Biochemical Journal 1999 342, part 3 481 496 2-s2.0-0033568661 10.1042/0264-6021:3420481 (Pubitemid 29452631)
25. Sen C. K., Packer L., Antioxidant and redox regulation of gene transcription. The FASEB Journal 1996 10 7 709 720 2-s2.0-0029984062 (Pubitemid 26172817)
26. Nikitovic D., Holmgren A., Spyrou G., Inhibition of AP-1 DNA binding by nitric oxide involving conserved cysteine residues in Jun and Fos. Biochemical and Biophysical Research Communications 1998 242 1 109 112 2-s2.0-0000128590 10.1006/bbrc.1997.7930 (Pubitemid 28412386)
27. Rainwater R., Parks D., Anderson M. E., Tegtmeyer P., Mann K., Role of cysteine residues in regulation of p53 function. Molecular and Cellular Biology 1995 15 7 3892 3903 2-s2.0-0029013621
28. Wu H. H., Momand J., Pyrrolidine dithiocarbamate prevents p53 activation and promotes p53 cysteine residue oxidation. The Journal of Biological Chemistry 1998 273 30 18898 18905 2-s2.0-0032563191 10.1074/jbc.273.30.18898 (Pubitemid 28366277)
29. Meister A., Anderson M. E., Glutathione. Annual Review of Biochemistry 1983 52 711 760 2-s2.0-0020972417 (Pubitemid 13030692)
30. Messina J. P., Lawrence D. A., Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. Journal of Immunology 1989 143 6 1974 1981 2-s2.0-0024426194 (Pubitemid 19241216)
31. Lu S. C., Ge J. L., Loss of suppression of GSH synthesis at low cell density in primary cultures of rat hepatocytes. American Journal of Physiology 1992 263 6, part 1 C1181 C1189 2-s2.0-0027052233 (Pubitemid 23024423)
32. Holmgren A., Regulation of ribonucleotide reductase. Current Topics in Cellular Regulation 1981 19 47 76 2-s2.0-0019749063
33. Carretero J., Obrador E., Anasagasti M. J., Martin J. J., Vidal-Vanaclocha F., Estrela J. M., Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clinical and Experimental Metastasis 1999 17 7 567 574 2-s2.0-0033506111 10.1023/A:1006725226078 (Pubitemid 30337130)
34. Huang Z. Z., Chen C., Zeng Z., Yang H., Oh J., Chen L., Lu S. C., Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. The FASEB Journal 2001 15 1 19 21 2-s2.0-0035227318
35. Marengo B., Ciucis C. D., Ricciarelli R., Romano P., Passalacqua M., Marinari U. M., Pronzato M. A., Domenicotti C., DNA oxidative damage of neoplastic rat liver lesions. Oncology Reports 2010 23 5 1241 1246 2-s2.0-77950823117 10.3892/or-00000756
36. Carretero J., Obrador E., Esteve J. M., Ortega A., Pellicer J. A., Sempere F. V., Estrela J. M., Tumoricidal activity of endothelial cells: inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro. The Journal of Biological Chemistry 2001 276 28 25775 25782 2-s2.0-0035854787 10.1074/jbc.M101148200 (Pubitemid 37412778)
37. Costantini P., Jacotot E., Decaudin D., Kroemer G., Mitochondrion as a novel target of anticancer chemotherapy. Journal of the National Cancer Institute 2000 92 13 1042 1053 2-s2.0-0034608786 (Pubitemid 30616479)
38. Joseph B., Marchetti P., Formstecher P., Kroemer G., Lewensohn R., Zhivotovsky B., Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene 2002 21 1 65 77 2-s2.0-0037012040 10.1038/sj.onc.1205018 (Pubitemid 34076379)
39. Pompella A., Corti A., Paolicchi A., Giommarelli C., Zunino F., γ -Glutamyltransferase, redox regulation and cancer drug resistance. Current Opinion in Pharmacology 2007 7 4 360 366 2-s2.0-34548081774 10.1016/j.coph.2007. 04.004 (Pubitemid 47289260)
40. Pompella A., De Tata V., Paolicchi A., Zunino F., Expression of γ -glutamyltransferase in cancer cells and its significance in drug resistance. Biochemical Pharmacology 2006 71 3 231 238 2-s2.0-29144438058 10.1016/j.bcp.2005.10.005 (Pubitemid 41817283)
41. Roomi M. W., Gaal K., Yuan Q. X., French B. A., Fu P., Bardag-Gorce F., French S. W., Preneoplastic liver cell foci expansion induced by thioacetamide toxicity in drug-primed mice. Experimental and Molecular Pathology 2006 81 1 8 14 (Pubitemid 43949620)
42. Hanigan M. H., Frierson H. F. Jr., Brown J. E., Lovell M. A., Taylor P. T., Human ovarian tumors express γ -glutamyl transpeptidase. Cancer Research 1994 54 1 286 290 2-s2.0-0028120946 (Pubitemid 24042125)
43. Murata J., Ricciardi-Castagnoli P., Mange P. D., Martin F., Juillerat-Jeanneret L., Microglial cells induce cytotoxic effects toward colon carcinoma cells: measurement of tumor cytotoxicity with a gamma-glutamyl transpeptidase assay. International Journal of Cancer 1997 70 2 169 174 (Pubitemid 27107413)
44. Tsutsumi M., Sakamuro D., Takada A., Zang S. C., Furukawa T., Taniguchi N., Detection of a unique γ -glutamyl transpeptidase messenger RNA species closely related to the development of hepatocellular carcinoma in humans: a new candidate for early diagnosis of hepatocellular carcinoma. Hepatology 1996 23 5 1093 1097 2-s2.0-0030004886
45. Supino R., Mapelli E., Sanfilippo O., Silvestro L., Biological and enzymatic features of human melanoma clones with different invasive potential. Melanoma Research 1992 2 5-6 377 384 2-s2.0-0027406950 (Pubitemid 23084485)
46. Tager M., Ittenson A., Franke A., Frey A., Gassen H. G., Ansorge S., γ -glutamyl transpepsidase-cellular expression in populations of normal human mononuclear cells and patients suffering from leukemias. Annals of Hematology 1995 70 5 237 242 2-s2.0-0028989695 10.1007/s002770050062
47. Prezioso J. A., Wang N., Duty L., Bloomer W. D., Gorelik E., Enhancement of pulmonary metastasis formation and γ -glutamyltranspeptidase activity in B16 melanoma induced by differentiation in vitro. Clinical and Experimental Metastasis 1993 11 3 263 274 2-s2.0-0027269921 (Pubitemid 23138525)
48. Obrador E., Carretero J., Ortega A., Medina I., Rodilla V., Pellicer J. A., Estrela J. M., γ -glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 2002 35 1 74 81 2-s2.0-0036140408 10.1053/jhep.2002.30277 (Pubitemid 34032545)
49. Bard S., Noel P., Chauvin F., Quash G., γ -glutamyltranspeptidase activity in human breast lesions: an unfavourable prognostic sign. British Journal of Cancer 1986 53 5 637 642 2-s2.0-0022653271 (Pubitemid 16114624)
50. Corti A., Duarte T. L., Giommarelli C., De Tata V., Paolicchi A., Jones G. D. D., Pompella A., Membrane gamma-glutamyl transferase activity promotes iron-dependent oxidative DNA damage in melanoma cells. Mutation Research 2009 669 1-2 112 121 2-s2.0-70349152500 10.1016/j.mrfmmm.2009.05.010
51. Perego P., Paolicchi A., Tongiani R., Pompella A., Tonarelli P., Carenini N., Romanelli S., Zunino F., The cell-specific anti-proliferative effect of reduced glutathione is mediated by gamma-glutamyl transpeptidase-dependent extracellular pro-oxidant reactions. International Journal of Cancer 1997 71 2 246 250 (Pubitemid 27252998)
52. del Bello B., Paolicchi A., Comporti M., Pompella A., Maellaro E., Hydrogen peroxide produced during γ -glutamyl transpeptidase activity is involved in prevention of apoptosis and maintenance of proliferation in U937 cells. The FASEB Journal 1999 13 1 69 79 2-s2.0-0032905740 (Pubitemid 29038276)
53. Reber U., Wüllner U., Trepel M., Baumgart J., Seyfried J., Klockgether T., Dichgans J., Weller M., Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells. The role of BCL-2. Biochemical Pharmacology 1998 55 3 349 359 2-s2.0-17744402925 10.1016/S0006-2952(97)00480-2 (Pubitemid 28021748)
54. Anderson C. P., Tsai J. M., Meek W. E., Liu R. M., Tang Y., Forman H. J., Reynolds C. P., Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis. Experimental Cell Research 1999 246 1 183 192 2-s2.0-0033540268 10.1006/excr.1998.4303 (Pubitemid 29393758)
55. Friesen C., Kiess Y., Debatin K. M., A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death and Differentiation 2004 11 supplement 1 S73 S85 2-s2.0-4344625883 10.1038/sj.cdd.4401431 (Pubitemid 39136800)
56. D'Alessio M., Cerella C., Amici C., Pesce C., Coppola S., Fanelli C., De Nicola M., Cristofanon S., Clavarino G., Bergamaschi A., Magrini A., Gualandi G., Ghibelli L., Glutathione depletion up-regulates Bcl-2 in BSO-resistant cells. The FASEB Journal 2004 18 13 1609 1611 2-s2.0-9444292402 10.1096/fj.04-1813fje (Pubitemid 39561649)
57. Wondrak G. T., Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxidants and Redox Signaling 2009 11 12 3013 3069 2-s2.0-70449107252 10.1089/ars.2009.2541
58. 2-terminal kinase and up-regulation of death receptors. Cancer Research 2006 66 23 11416 11423 2-s2.0-33845794791 10.1158/0008-5472.CAN-06-0409 (Pubitemid 46009973)
59. Domenicotti C., Marengo B., Verzola D., Garibotto G., Traverso N., Patriarca S., Maloberti G., Cottalasso D., Poli G., Passalacqua M., Melloni E., Pronzato M. A., Marinari U. M., Role of PKC- δ activity in glutathione-depleted neuroblastoma cells. Free Radical Biology and Medicine 2003 35 5 504 516 2-s2.0-10744226728 10.1016/S0891-5849(03)00332-0 (Pubitemid 37289160)
60. Marengo B., de Ciucis C., Ricciarelli R., Passalacqua M., Nitti M., Zingg J. M., Marinari U. M., Pronzato M. A., Domenicotti C., PKC δ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage. PLoS ONE 2011 6 2 2-s2.0-79951534617 10.1371/journal.pone.0014661 e14661
61. Bailey H. H., Ripple G., Tutsch K. D., Arzoomanian R. Z., Alberti D., Feierabend C., Mahvi D., Schink J., Pomplun M., Mulcahy R. T., Wilding G., Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. Journal of the National Cancer Institute 1997 89 23 1789 1796 2-s2.0-0030658870 (Pubitemid 27516233)
62. Hernandez-Breijo B., Monserrat J., Ramirez-Rubio S., Cuevas E. P., Vara D., Diaz-Laviada I., Fernandez-Moreno M. D., Roman I. D., Gisbert J. P., Guijarro L. G., Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World Journal of Gastroenterology 2011 17 34 3899 3911
63. Hamilton D., Jian H. W., Batist G., Structure-based identification of novel human γ -glutamylcysteine synthetase inhibitors. Molecular Pharmacology 2007 71 4 1140 1147 2-s2.0-33947409143 10.1124/mol.106.024778 (Pubitemid 46457017)
64. Godwin A. K., Meister A., O'Dwyer P. J., Chin Shiou Huang, Hamilton T. C., Anderson M. E., High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proceedings of the National Academy of Sciences of the United States of America 1992 89 7 3070 3074 2-s2.0-0026594392
65. Mulcahy R. T., Untawale S., Gipp J. J., Transcriptional up-regulation of γ -glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells. Molecular Pharmacology 1994 46 5 909 914 2-s2.0-0028171395 (Pubitemid 24364104)
66. Benlloch M., Ortega A., Ferrer P., Segarra R., Obrador E., Asensi M., Carretero J., Estrela J. M., Acceleration of glutathione efflux and inhibition of γ-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. The Journal of Biological Chemistry 2005 280 8 6950 6959 2-s2.0-14844286405 10.1074/jbc.M408531200 (Pubitemid 40341251)
67. 2-induced injury by 2,3-dimethoxy-1,4-naphthoquinone. Free Radical Biology and Medicine 1993 15 1 57 67 2-s2.0-0027271845 10.1016/0891-5849(93)90125-E (Pubitemid 23171443)
68. Hochwald S. N., Rose D. M., Brennan M. F., Burt M. E., Elevation of glutathione and related enzyme activities in high-grade and metastatic extremity soft tissue sarcoma. Annals of Surgical Oncology 1997 4 4 303 309 2-s2.0-0031156696 (Pubitemid 127725233)
69. Lewis A. D., Hayes J. D., Wolf C. R., Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 1988 9 7 1283 1287 2-s2.0-0023942684
70. Kuo M. T., Bao J. J., Furuichi M., Yamane Y., Gomi A., Saharaj N., Masuzawa T., Ishikawa T., Frequent coexpression of MRP/GS-X pump and γ -glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochemical Pharmacology 1998 55 5 605 615 2-s2.0-0032031395 10.1016/S0006-2952(97)00494-2 (Pubitemid 28077819)
71. Oguri T., Fujiwara Y., Isobe T., Katoh O., Watanabe H., Yamakido M., Expression of γ -glutamylcysteine synthetase (γ -GCS) and Multidrug Resistance-associated Protein (MRP), but not human canalicular Multispecific Organic Anion Transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. British Journal of Cancer 1998 77 7 1089 1096 2-s2.0-0031881908
72. Balendiran G. K., Dabur R., Fraser D., The role of glutathione in cancer. Cell Biochemistry and Function 2004 22 6 343 352 2-s2.0-8744226622 10.1002/cbf.1149 (Pubitemid 39518098)
73. McLellan L. I., Wolf C. R., Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resistance Updates 1999 2 3 153 164 2-s2.0-0033150345 10.1054/drup.1999.0083 (Pubitemid 29398151)
74. Adler V., Yin Z., Fuchs S. Y., Benezra M., Rosario L., Tew K. D., Pincus M. R., Sardana M., Henderson C. J., Wolf C. R., Davis R. J., Ronai Z., Regulation of JNK signaling by GSTp. The EMBO Journal 1999 18 5 1321 1334 2-s2.0-0033105414 (Pubitemid 29110316)
75. Ono K., Han J., The p38 signal transduction pathway activation and function. Cellular Signalling 2000 12 1 1 13 2-s2.0-0033965158 10.1016/S0898-6568(99)00071-6 (Pubitemid 30017963)
76. Marengo B., De Ciucis C. G., Ricciarelli R., Furfaro A. L., Colla R., Canepa E., Traverso N., Marinari U. M., Pronzato M. A., Domenicotti C., p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment. Cell Death and Disease 2013 4, article e589
77. Dhakshinamoorthy S., Jaiswal A. K., Small Maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H:quinone oxidoreductase1 gene. The Journal of Biological Chemistry 2000 275 51 40134 40141 2-s2.0-0034704137 10.1074/jbc.M003531200 (Pubitemid 32064640)
78. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., Oyake T., Hayashi N., Satoh K., Hatayama I., Yamamoto M., Nabeshima Y. I., An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communications 1997 236 2 313 322 2-s2.0-0031577292 10.1006/bbrc.1997.6943 (Pubitemid 27373291)
79. Rushworth S. A., MacEwan D. J., O'Connell M. A., Lipopolysaccharide- induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. Journal of Immunology 2008 181 10 6730 6737 2-s2.0-58149181985
80. Ohta T., Iijima K., Miyamoto M., Nakahara I., Tanaka H., Ohtsuji M., Suzuki T., Kobayashi A., Yokota J., Sakiyama T., Shibata T., Yamamoto M., Hirohashi S., Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Research 2008 68 5 1303 1309 2-s2.0-40449107193 10.1158/0008-5472.CAN-07-5003 (Pubitemid 351346836)
81. Jiang T., Chen N., Zhao F., Wang X. J., Kong B., Zheng W., Zhang D. D., High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Research 2010 70 13 5486 5496 2-s2.0-77954351631 10.1158/0008-5472.CAN- 10-0713
82. Shibata T., Kokubu A., Gotoh M., Ojima H., Ohta T., Yamamoto M., Hirohashi S., Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008 135 4 1358.e4 1368.e4 2-s2.0-53049105119 10.1053/j.gastro.2008.06.082
83. Shibata T., Ohta T., Tong K. I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S., Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13568 13573 2-s2.0-51649130168 10.1073/pnas.0806268105
84. Otterbein L. E., Zuckerbraun B. S., Haga M., Liu F., Song R., Usheva A., Stachulak C., Bodyak N., Neal Smith R., Csizmadia E., Tyagi S., Akamatsu Y., Flavell R. J., Billiar T. R., Tzeng E., Bach F. H., Choi A. M. K., Soares M. P., Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nature Medicine 2003 9 2 183 190 2-s2.0-0344284580 10.1038/nm817 (Pubitemid 36227720)
85. Otterbein L. E., Soares M. P., Yamashita K., Bach F. H., Heme oxygenase-1: unleashing the protective properties of heme. Trends in Immunology 2003 24 8 449 455 2-s2.0-0043268709 10.1016/S1471-4906(03)00181-9 (Pubitemid 36928103)
86. Jozkowicz A., Was H., Dulak J., Heme oxygenase-1 in tumors: is it a false friend? Antioxidants and Redox Signaling 2007 9 12 2099 2117 2-s2.0-35848942608 10.1089/ars.2007.1659 (Pubitemid 350059009)
87. Goodman A. I., Choudhury M., Da Silva J. L., Schwartzman M. L., Abraham N. G., Overexpression of the heme oxygenase gene in renal cell carcinoma. Proceedings of the Society for Experimental Biology and Medicine 1997 214 1 54 61 2-s2.0-0031024280
88. Maines M. D., Abrahamsson P. A., Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology 1996 47 5 727 733 2-s2.0-0030003896 10.1016/S0090-4295(96)00010-6 (Pubitemid 26172743)
89. Berberat P. O., Dambrauskas Z., Gulbinas A., Giese T., Giese N., Künzli B., Autschbach F., Meuer S., Büchler M. W., Friess H., Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clinical Cancer Research 2005 11 10 3790 3798 2-s2.0-21044452445 10.1158/1078-0432.CCR-04-2159 (Pubitemid 40685598)
90. Nowis D., Legat M., Grzela T., Niderla J., Wilczek E., Wilczynski G. M., Głodkowska E., Mrówka P., Issat T., Dulak J., Józkowicz A., Waś H., Adamek M., Wrzosek A., Nazarewski S., Makowski M., Stokłosa T., Jakóbisiak M., Gołab J., Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 2006 25 24 3365 3374 2-s2.0-33745074201 10.1038/sj.onc.1209378 (Pubitemid 43880305)
91. Marengo B., Balbis E., Patriarca S., De Ciucis C., Furfaro A., Nitti M., Marinari U. M., Pronzato M. A., Traverso N., Domenicotti C., GSH loss per se does not affect neuroblastoma survival and is not genotoxic. International Journal of Oncology 2008 32 1 121 127 2-s2.0-38749099759 (Pubitemid 351176069)
92. Furfaro A. L., Macay J. R., Marengo B., Nitti M., Parodi A., Fenoglio D., Marinari U. M., Pronzato M. A., Domenicotti C., Traverso N., Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. Free Radical Biology and Medicine 52 2 488 496
93. Schafer F. Q., Buettner G. R., Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biology and Medicine 2001 30 11 1191 1212 2-s2.0-0035371184 10.1016/S0891-5849(01)00480-4 (Pubitemid 32463931)
94. Shibata S., Tominaga K., Watanabe S., Glutathione protects against hypoxic/hypoglycemic decreases in 2-deoxyglucose uptake and presynaptic spikes in hippocampal slices. European Journal of Pharmacology 1995 273 1-2 191 195 2-s2.0-0028917918 10.1016/0014-2999(94)00727-O
95. Chakrapani H., Kalathur R. C., Maciag A. E., Citro M. L., Ji X., Keefer L. K., Saavedra J. E., Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorganic and Medicinal Chemistry 2008 16 22 9764 9771 2-s2.0-54849440996 10.1016/j.bmc.2008.09.063
96. Batist G., Tulpule A., Sinha B. K., Overexpression of a novel anionic glutathione transferase in multidrug-resistent human breast cancer cells. The Journal of Biological Chemistry 1986 261 33 15544 15549 2-s2.0-0023037085 (Pubitemid 17208781)
97. Wu J. H., Miao W., Hu L. G., Batist G., Identification and characterization of novel Nrf2 inducers designed to target the intervening region of keap1. Chemical Biology and Drug Design 2010 75 5 475 480 2-s2.0-77949993628 10.1111/j.1747-0285.2010.00955.x
98. Hamilton D., Batist G., TLK-199 Telik. IDrugs 2005 8 8 662 669 2-s2.0-23244453323 (Pubitemid 41093871)
99. Raza A., Galili N., Smith S., Godwin J., Lancet J., Melchert M., Jones M., Keck J. G., Meng L., Brown G. L., List A., Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009 113 26 6533 6540 2-s2.0-69249238115 10.1182/blood-2009-01-176032
100. Raza A., Galili N., Smith S. E., Godwin J., Boccia R. V., Myint H., Mahadevan D., Mulford D., Rarick M., Brown G. L., Schaar D., Faderl S., Komrokji R. S., List A. F., Sekeres M., A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer 2012 118 8 2138 2147
101. Tate S. S., Meister A., Serine-borate complex as a transition-state inhibitor of γ -glutamyl transpeptidase. Proceedings of the National Academy of Sciences of the United States of America 1978 75 10 4806 4809 2-s2.0-0042033156 (Pubitemid 9048623)
102. London R. E., Gabel S. A., Development and evaluation of a boronate inhibitor of γ -glutamyl transpeptidase. Archives of Biochemistry and Biophysics 2001 385 2 250 258 2-s2.0-0035862175 10.1006/abbi.2000.2169 (Pubitemid 32989281)
103. Han L., Hiratake J., Kamiyama A., Sakata K., Design, synthesis, and evaluation of γ -phosphono diester analogues of glutamate as highly potent inhibitors and active site probes of γ -glutamyl transpeptidase. Biochemistry 2007 46 5 1432 1447 2-s2.0-33846845012 10.1021/bi061890j (Pubitemid 46208491)
104. Fidias P., Novello S., Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010 28 34 5116 5123 2-s2.0-78650491373 10.1200/JCO.2010.30.7074
105. Matulonis U. A., Horowitz N. S., Campos S. M., Lee H., Lee J., Krasner C. N., Berlin S., Roche M. R., Duska L. R., Pereira L., Kendall D., Penson R. T., Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. Journal of Clinical Oncology 2008 26 35 5761 5766 2-s2.0-57449098425 10.1200/JCO.2008.17.0282
106. Townsend D. M., Pazoles C. J., Tew K. D., NOV-002, a mimetic of glutathione disulfide. Expert Opinion on Investigational Drugs 2008 17 7 1075 1083 2-s2.0-48249115538 10.1517/13543784.17.7.1075
107. Montero A. J., Jassem J., Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011 71 11 1385 1396 2-s2.0-79961196710 10.2165/11592590-000000000-00000
108. Townsend D. M., Tew K. D., Pharmacology of a mimetic of glutathione disulfide, NOV-002. Biomedicine and Pharmacotherapy 2009 63 2 75 78 2-s2.0-58949103855 10.1016/j.biopha.2008.08.019
109. Montero A. J., Diaz-Montero C. M., Deutsch Y. E., Hurley J., Koniaris L. G., Rumboldt T., Yasir S., Jorda M., Garret-Mayer E., Avisar E., Slingerland J., Silva O., Welsh C., Schuhwerk K., Seo P., Pegram M. D., Gluck S., Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Research and Treatment 2012 132 1 215 223
110. Zhang Y., Talalay P., Cho C. G., Posner G. H., A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proceedings of the National Academy of Sciences of the United States of America 1992 89 6 2399 2403 2-s2.0-0026577605
111. Ren D., Villeneuve N. F., Jiang T., Wu T., Lau A., Toppin H. A., Zhang D. D., Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proceedings of the National Academy of Sciences of the United States of America 2011 108 4 1433 1438 2-s2.0-79952122321 10.1073/pnas.1014275108
112. Zhan L., Zhang H., Zhang Q., Woods C. G., Chen Y., Xue P., Dong J., Tokar E. J., Xu Y., Hou Y., Fu J., Yarborough K., Wang A., Qu W., Waalkes M. P., Andersen M. E., Pi J., Regulatory role of KEAP1 and NRF2 in PPARgamma expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radical Biology and Medicine 2012 53 4 758 768
113. Fang J., Sawa T., Akaike T., Greish K., Maeda H., Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. International Journal of Cancer 2004 109 1 1 8 2-s2.0-0842308157 10.1002/ijc.11644 (Pubitemid 38165358)
114. Fang J., Sawa T., Akaike T., Akuta T., Sahoo S. K., Khaled G., Hamada A., Maeda H., In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Research 2003 63 13 3567 3574 2-s2.0-0038418359 (Pubitemid 36793037)
115. Cen D., Brayton D., Shahandeh B., Meyskens F. L., Farmer P. J., Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. Journal of Medicinal Chemistry 2004 47 27 6914 6920 2-s2.0-11144224746 10.1021/jm049568z (Pubitemid 40053779)
116. Fruehauf J. P., Meyskens F. L. III, Reactive oxygen species: a breath of life or death? Clinical Cancer Research 2007 13 3 789 794 2-s2.0-33847349283 10.1158/1078-0432.CCR-06-2082 (Pubitemid 46340350)
117. Lu J., Chew E. H., Holmgren A., Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proceedings of the National Academy of Sciences of the United States of America 2007 104 30 12288 12293 2-s2.0-34547644483 10.1073/pnas.0701549104 (Pubitemid 47206130)
118. Dai J., Weinberg R. S., Waxman S., Jing Y., Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999 93 1 268 277 2-s2.0-0032933610 (Pubitemid 29019412)
119. Maeda H., Hori S., Ohizumi H., Segawa T., Kakehi Y., Ogawa O., Kakizuka A., Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death and Differentiation 2004 11 7 737 746 2-s2.0-3543084996 10.1038/sj.cdd.4401389 (Pubitemid 39023120)
120. Lushchak V. I., Glutathione homeostasis and functions: potential targets for medical interventions. Journal of Amino Acids 2012 2012 26 736837 10.1155/2012/736837
121. Cowan K. H., Batist G., Tulpule A., Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proceedings of the National Academy of Sciences of the United States of America 1986 83 24 9328 9332 2-s2.0-0038134267 (Pubitemid 17223354)
122. Hayes J. D., McMahon M., NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in Biochemical Sciences 2009 34 4 176 188 2-s2.0-63549121490 10.1016/j.tibs.2008.12.008
123. Maher J. M., Dieter M. Z., Aleksunes L. M., Slitt A. L., Guo G., Tanaka Y., Scheffer G. L., Chan J. Y., Manautou J. E., Chen Y., Dalton T. P., Yamamoto M., Klaassen C. D., Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 2007 46 5 1597 1610 2-s2.0-36349015332 10.1002/hep.21831 (Pubitemid 350155541)